In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC ... confirming that the event was not related to the investigational ...
Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...
The COVID-19 and flu vaccine maker said it expected full-year revenue of ... Shares of Novavax fell about 5% Tuesday morning.
Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...
The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared ...
Novavax's COVID vaccine brought in sales of $38.21 million for the third ... which Novavax said this week got the green light ...
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...